ARFGAP3 and cancer: Pathway analysis for rituximab-resistant cell lines showed enriched proteins (CYTH1, SEC24D, VPS25, and ARFGAP3) involved in membrane trafficking, which is a pathway mediating many processes and enzyme functions that cancer cells can use to promote tumorigenesis and drug responses [45].